Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Expands Gold Footprint in BC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the... see more

Current News (NDAQ:ALDX)

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Business Wire December 15, 2025

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Business Wire November 13, 2025

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Business Wire November 11, 2025

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Business Wire November 6, 2025

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Business Wire October 28, 2025

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Business Wire September 3, 2025

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Business Wire August 28, 2025

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Business Wire August 19, 2025

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Business Wire August 6, 2025
View More News ››

Opinion & Analysis (NDAQ:ALDX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALDX)

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway
coolfooldumbguy - December 16, 2025

Sell buddy sell.Wow.

Otherwise you guys out there will be losing your shorts with this one
coolfooldumbguy - April 3, 2025

ALDX.....LoL....even The Pumpers are pumping their book

on this "Train Wreck" Sheesh
Iseneschal - October 16, 2023

WILL ALDEYRA HIT THE BULL’S EYE IN DRY EYE?

$ALDX    Excited to share our latest coverage on Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) which announced positive...
AviseAnalytics - July 19, 2022

it's a buy today for me

missed the bottom,but it is way oversold,so paid $5.76 per share and looking for a quick rebound of this one glta shareholders.
coolfooldumbguy - June 25, 2019

positive results

we will see what happens in April with this stock,so glta.
coolfooldumbguy - March 31, 2019
View more Bullboard ››

Vesalius Longevity Labs

Vesalius Longevity Labs

View More »

Podcasts